Uphill Climb For Gedeon Richter's Cariprazine After Delayed EU OK
Executive Summary
Gedeon Richter has finally had its antipsychotic cariprazine approved in the EU for treating schizophrenia - but its delay to market could dampen demand for the drug unless it can differentiate itself from rivals.
You may also be interested in...
Allergan Hopes To Add Bipolar Depression To Vraylar's Label
With Phase III success in bipolar depression, Allergan plans an sNDA in 2018 to add that indication to the atypical antipsychotic's label, which includes schizophrenia and bipolar mixed or manic episodes.
Allergan, Gedeon Richter Unbowed By Cariprazine MDD Phase III Trial Failure
Allergan and Gedeon Richter have hit a buffer in the development of their antipsychotic cariprazine in the additional indication of major depressive disorder, but they plan to proceed with a further pivotal trial, and mollified analysts with the announcement of a filing timeline to bolster the drug's label in schizophrenia.
Allergan/Richter’s Antipsychotic Vraylar Offers New Mechanism Of Action
Schizophrenia and bipolar disorder treatment will launch in first quarter of 2016.